ClinicalTrials.gg
CompletedNCT06103773Updated Oct 1, 2026

A Study of Single and Multiple Oral Doses of TollB-001

A Phase 1 interventional study of TollB-001 tablets and TollB-001 placebo in Rheumatoid Arthritis, sponsored by Toll Biotech Co. Ltd. (Beijing). Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Toll Biotech Co. Ltd. (Beijing) · Phase 1, Interventional, and Treatment

Updated Oct 1, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Enrollment
128th of 217
98 · median 134
Started
2023
with 18 others
Phase 1
54 of 249
20 open now
Registered
173rd of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 128th largest by enrollment of the 217 interventional ones that give a count, is one of 19 that started in 2023, is one of 54 in phase 1, and was the 173rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

The primary objective is to evaluate the safety and tolerability of TollB-001 following the administration of single or multiple oral doses in healthy adult subjects

Read the detailed description

This is a Phase I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of single or multiple dose(s) of TollB-001 administered orally in healthy adult subjects and the food effect on the PK of a single dose of TollB-001 with a randomized, open-label and two-period crossover design.

This study includes three parts. Part A: single ascending dose (SAD) study; Part B: multiple ascending dose (MAD) study; and Part C: FE study.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects between the age of 18 and 45 (both inclusive) when signing the form (ICF)
  2. Able to give a signed written ICF (the consent form must be signed by the subject prior to any study-specific procedures); have a full understanding of the study content, procedures, and possible AEs; and be willing and able to comply with study procedures and follow-up examinations
  3. (BMI, weight [kg]/height2 [m2]) within 19.0-26.0 kg/m2 (both inclusive), with total body weight > 50 kg for male subjects and > 45 kg for female subjects.
  4. The subjects must be willing to use efficient physical methods with a contraceptive failure rate of\<1% with their reproductive age partners within 90 days from signing the ICF to the last administration of the drug (such as condoms , intrauterine devices)
  5. Male subjects must also be willing to refrain from donating sperm for 90 days from the first administration of the investigational drug to the last administration of the investigational drug
  6. Results of vital signs, physical examination, laboratory examinations, abdominal and urinary B-ultrasound, 12-lead , and other examination are normal or abnormal but not . corrected for heart rate according to Fridericia's formula (QTcF) must be within the following ranges: QTcF ≤ 450 msec for male subjects, and QTcF ≤ 470 msec for female subjects. Assessment may be repeated if deemed appropriate by the investigator.
  7. Ability to swallow all IMPs.

Exclusion criteria

Exclusion Criteria:

Subjects were excluded if they meet any of the following exclusion criteria:

  1. Known or suspected allergy or to any component of TollB-001, known allergic constitution or allergy to two or more foods or drugs.
  2. Severe gastrointestinal diseases, such as patients who have undergone major gastrointestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs (except for cholecystectomy, appendectomy, hernia repair), or medical history of ulcer, gastrointestinal bleeding, gastritis, etc.
  3. History or clinical manifestations of any gastrointestinal, gallbladder or biliary tract, renal, urologic, pulmonary, neurological, cardiovascular, endocrinological, hematological, immunologic, dermatologic, metabolic disorder, or psychiatric disease (as determined by the investigator).
  4. Current or chronic history of liver disease or known hepatic ,or clinically significant of biliary abnormalities , or clinically significant abnormal results of liver function test at screening, including alanine amino transferase () or/and aspartate aminotransferase (AST) > 1.5 × (ULN)or/and total > ULN.
  5. \< 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening or on Day-1.
  6. Current or history of clinically significant cardiac arrhythmias (symptomatic or asymptomatic).
  7. Serious infection within 3 months prior to dosing or symptoms of infection within 7 days before dosing, including acute and chronic infections and local infections (bacterial, viral, parasitic, fungal, or other opportunistic pathogens), which is inappropriate to participant as deemed by the investigator.
  8. Major illness or surgery within 3 months before dosing ,or planned surgery during the study period.
  9. Intolerance to venipuncture.
  10. Participation in any clinical study or received any other product or device within 4 weeks prior to the first dose or 5 times the half-life of the specific drug/biologics(whichever is longer), or plan to take an investigational agent during the study.
  11. Donated blood > 400 mL or significant blood loss (equivalent to 400 mL), or received blood transfusion within 3 months of prior to screening, or have plans to donate blood during the study.
  12. History of within 5 years prior to screening (excluding non-melanoma skin cancer that has been resected).
  13. Positive results of any of the following tests at screening: serum surface antigen (HBsAg), virus (HCV RNA or HCV antibodies [Ab]), 1 and 2 (HIV)Ab, or Treponema pallidum (TP) Ab.
  14. Active tuberculosis (TB) infection indicated by chest radiography orγ-interferon at screening or within 3 months prior to screening. TB test positive, or active or latent TB infection as discretion of the investigator according to clinical practice, or history of TB, or currently receiving treatment for this disease.
  15. Plans to receive administration of any within 4 weeks before dosing or up to 30 days after the last dose of IMP.
  16. Use of drugs, including prescription, over-the-counter medications herbal products, vitamins, and minerals, within 2 weeks prior to the first dose or within 5 times the elimination half-life of the medication prior to first dosing(whichever is longer).
  17. Participated in strenuous exercise from 48 hours prior to Day-1 .
  18. Unwilling to refrain from any food or beverage containing caffeine or producing xanthine after metabolism (e.g., tea, coffee, chocolate, cola, red cattle) from 24 hours prior to Day -1 and during the study.
  19. Use of food or beverages likely to influence liver metabolism, within 14 days prior to the first dose of the IMP (e.g., star fruit, pomelos, grapefruit, and Seville oranges). Use of any drugs or nutrients known to modulate cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A and transporter OATP1B1,1B3, OAT3, OCT2 activity (refer to Appendix 3) or any strong or moderate inhibitors or inducers ofCYP1A2, BCRP, OATP1B1, OATP1B3, and OAT3 (refer to Appendix 4) starting from 14 days priorto dose administration on Day 1.
  20. History of significant alcohol abuse within 6 months prior to screening or use of more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol 40% or 150 mL of wine) within 90 days prior to screening or alcohol breath test >0.0mg/100ml at screening, or unwilling to refrain from consumption of alcohol during the study.
  21. Use of tobacco or nicotine products or smoking within 90 days (more than 5 cigarettes per day) prior to screening and unwilling to refrain from 24 hours prior to Day -1 and during the study.
  22. Drug abuse or those who have taken drugs (such as cocaine, phencyclidine, etc.) within one year prior to screening (consultation); Or those who are positive for urine drug abuse screening (methamphetamine, ketamine, MDMA ,tetrahydrocannabinoid acid, morphine) during screening.
  23. Women who are lactating or positive pregnancy test within at screening or during the study period, or planning to become pregnant during the study period.
  24. Acute illness occurs or concomitant medication required from screening to dosing.
  25. Constipated or irregular bowel movements.
  26. Any other situation that researchers believe may affect the subject's ability to provide or follow the trial protocol, or the subject's participation in the trial may affect the trial results or their own safety.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    SAD-TollB-001 50mg Dosage groups

    drug:TollB-001 tablets(50mg,single-dose, on the first day)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    SAD-TollB-001 100mg Dosage groups

    drug:TollB-001 tablets (100mg,single-dose, on the first day)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    SAD-TollB-001 200mg Dosage groups

    drug:TollB-001 tablets (200mg,single-dose, on the first day)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    SAD-TollB-001 400mg Dosage groups

    drug:TollB-001 tablets (400mg,single-dose, on the first day)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    SAD-TollB-001 800mg Dosage groups

    drug:TollB-001 tablets (600mg,single-dose, on the first day)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    MAD- TollB-001 100mg Dosage groups

    drug:TollB-001 tablets (50mg,Multiple-dose, once per day for 10 days)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    MAD- TollB-001 200mg Dosage groups

    drug:TollB-001 tablets (100mg,Multiple-dose, once per day for 10 days)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    MAD-TollB-001 400mg Dosage groups

    drug:TollB-001 tablets (200mg,Multiple-dose, once per day for 10 days)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    MAD-TollB-001 800mg Dosage groups

    drug:TollB-001 tablets (400mg,Multiple-dose, once per day for 10 days)

    Drug: TollB-001 tablets · Drug: TollB-001 placebo

  • Experimental
    FE-Low Dosage groups

    drug:TollB-001 tablets(Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in the first period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 10 days)

    Drug: TollB-001 tablets

  • Experimental
    FE-High Dosage groups

    drug:TollB-001 tablets Subjects in the fasting-fed sequence group will be administered with TollB-001 under fasting condition in the first period and under fed condition in the second period; subject in the fed-fasting sequence group will be administered with TollB-001 under fed condition in thefirst period and under fasting condition in the second period. The two periods of cross-administration will have a washout period of 10 days)

    Drug: TollB-001 tablets

Interventions

  • TollB-001 treatment

    Also known as: TollB-001

  • DrugTollB-001 placebo

    TollB-001 Placebo

06

What researchers measure

Primary outcomes

  1. Red blood cell count(physiological parameter) by investigator

    Red blood cell count

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  2. hematocrit(physiological parameter) by investigator

    hematocrit

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  3. hemoglobin(physiological parameter) by investigator

    hemoglobin

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  4. white blood cell count(physiological parameter) by investigator

    white blood cell count

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  5. whiteblood cell differential count(physiological parameter) by investigator

    whiteblood cell differential count

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  6. plateletcount(physiological parameter) by investigator

    plateletcount

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  7. Alanine aminotransferase(physiological parameter) by investigator

    Alanine aminotransferase

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  8. aspartateaminotransferase(physiological parameter) by investigator

    aspartateaminotransferase

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  9. alkaline phosphatase(physiological parameter) by investigator

    alkaline phosphatase

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  10. gamma-glutamyl transpeptidase(physiological parameter) by investigator

    gamma-glutamyl transpeptidase

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  11. total bilirubin(physiological parameter) by investigator

    total bilirubin

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  12. direct bilirubin(physiological parameter) by investigator

    direct bilirubin

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  13. blood ureanitrogen (or blood urea)(physiological parameter) by investigator

    blood ureanitrogen (or blood urea)

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  14. creatinine(physiological parameter) by investigator

    creatinine

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  15. glucose(physiological parameter) by investigator

    glucose

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  16. total protein(physiological parameter) by investigator

    total protein

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  17. creatine kinase(physiological parameter) by investigator

    creatine kinase

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  18. Activated partial thromboplastin time(physiological parameter) by investigator

    Activated partial thromboplastin time

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  19. prothrombin time(physiological parameter) by investigator

    prothrombin time

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  20. internationalnormalized ratio(physiological parameter) by investigator

    internationalnormalized ratio

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  21. fibrinogen(physiological parameter) by investigator

    fibrinogen

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  22. urine pH(physiological parameter) by investigator

    urine pH

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  23. urine specific gravity(physiological parameter) by investigator

    urine specific gravity

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  24. urine glucose(physiological parameter) by investigator

    urine glucose

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  25. urine protein(physiological parameter) by investigator

    urine protein

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  26. urobilinogen(physiological parameter) by investigator

    urobilinogen

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  27. urine bilirubin(physiological parameter) by investigator

    urine bilirubin

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  28. urine leukocyte(physiological parameter) by investigator

    urine leukocyte

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  29. urine ketone body(physiological parameter) by investigator

    urine ketone body

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  30. urine red blood cells(physiological parameter) by investigator

    urine red blood cells

    Time frame: Baseline(Screening)up to last follow-up visit(SAD:Screening up to Week 1;MAD:Screening up to Week 2;FE:Screening up to Week 2 plus 10 days)

  31. AE/SAE monitoring by ToxicityGrading Scale for Healthy Adults and Volunteers Enrolled in Preventative Vaccine Trials,2007 (70 FR 22664)

    AE/SAE monitoring

    Time frame: First dose up to last follow-up visit(for a maximum of 20 days)

  32. physical examination(physiological parameter) by investigator

    The assessments of general appearance, head(including ears, eyes, nose, throat), neck, skin, cardiovascular system, respiratory system,abdominal system, nervous system, musculoskeletal system, and lymphatic system

    Time frame: First dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 ,Day11,Day14or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit.

  33. blood pressure(systolic pressure and diastolic pressure)(physiological parameter) by investigator

    blood pressure(systolic pressure and diastolic pressure)

    Time frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

  34. pulse(physiological parameter) by investigator

    pulse

    Time frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

  35. respiratory rate(physiological parameter) by investigator

    respiratory rate

    Time frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

  36. body temperature(physiological parameter) by investigator

    body temperature

    Time frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.

  37. 12-lead ECGs

    ECGs done in triplicate; heart rate, PR interval, QT and QTc interval and QRS duration

    Time frame: For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit.

  38. B-ultrasound(physiological parameter) by investigator

    liver, gallbladder, spleen, pancreas, kidney and bladder

    Time frame: For a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day14 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit.

07

Study locations

1 site
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 611130, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Apr 2025, 18 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 18 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jun 2024 → Apr 2025 and completion Jun 2024 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 27, 2023
StartActual
Sep 28, 2023
Primary completionActual
Apr 7, 2025was Jun 2024
CompletionActual
Apr 7, 2025was Jun 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 1, 2026
Primary completion
Jun 9, 2024→Apr 7, 2025 (actual)
Oct 1, 2026
Study completion
Jun 9, 2024→Apr 7, 2025 (actual)
Oct 1, 2026
Enrollment
122 (estimated)→98 (actual)
Oct 1, 2026
Interventions
Arms removed: SAD-TollB-001 1000mg Dosage groups
Oct 1, 2026
Primary outcomes
7 time frame changed
What changed in the outcomes
  • Time framephysical examination(physiological parameter) by investigatorFirst dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit. → First dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 ,Day11,Day14or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit.
  • Time frameblood pressure(systolic pressure and diastolic pressure)(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  • Time framepulse(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  • Time framerespiratory rate(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  • Time framebody temperature(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
  • Time frame12-lead ECGsFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day9 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit.
  • Time frameB-ultrasound(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day9 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day14 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit.
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Completed
    Primary completion Jun 9, 2024→Apr 7, 2025 (now actual)
    Study completion Jun 9, 2024→Apr 7, 2025 (now actual)
    Enrollment 122 (estimated)→98 (actual)
    Primary outcomes 7 time frame changed
    What changed in the outcomes
    • Time framephysical examination(physiological parameter) by investigatorFirst dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit. → First dose up to last follow-up visit(for a maximum of 20 days);SAD:Screening,Day2,Day5 or ET Visit;MAD:Screening,Day3,Day6,Day9 ,Day11,Day14or ET Visit;FE:Screening,Period 1 Day2,Period 1 Day5;Period 2 Day-1,Period 2 Day2,Period 2 Day5 or ET Visit.
    • Time frameblood pressure(systolic pressure and diastolic pressure)(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
    • Time framepulse(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
    • Time framerespiratory rate(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
    • Time framebody temperature(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay9 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 toDay14 or ET Visit;FE:Screening,Period 1 Day1 to Day5;Period 2 Day-1 to Day5 or ET Visit.
    • Time frame12-lead ECGsFor a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day9 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day1 to Day5 or ET Visit;MAD:Screening,Day1 to Day14 or ET Visit;FE:Screening,Period 1 Day1,Period 1 Day3,Period 1 Day5;Period 2 Day-1,Period 2 Day1,Period 2 Day3,Period 2 Day5 or ET Visit.
    • Time frameB-ultrasound(physiological parameter) by investigatorFor a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day9 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit. → For a maximum of 20 days;SAD:Screening,Day5 or ET Visit;MAD:Screening,Day14 or ET Visit;FE:Screening,Period 1 Day5;Period 2 Day5 or ET Visit.
    Interventions Arms removed: SAD-TollB-001 1000mg Dosage groups
    + 3 other changes: contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06103773
Lead sponsor
Toll Biotech Co. Ltd. (Beijing)
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Sep 28, 2023
Primary completion
Apr 7, 2025
Completion
Apr 7, 2025
Last update
Oct 1, 2026

Study contacts

wen he
study director · Chengdu Fifth People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TOLLB-001

Start the discussion